Clinical Trial

Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.

Study acronym: MAZEPPA
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
MAZEPPA is open-label, phase II study to assess the efficacy of a genomic-driven maintenance therapy in terms of PFS in Pancreatic ductal adenocarcinoma (PDAC) patients with disease controlled after 4 months of mFOLFIRINOX chemotherapy as following: Patients with a BRCAness somatic profile: olaparib Arm A. Patients with no BRCAness profile and with KRAS mutation randomization between durvalumab plus selumetinib Arm B, versus FOLFIRI Arm C.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-04-14; most recent amendment 2025-07-22.
Status change: Recruiting → Active, Not Recruiting 2024-01-03
Status change: Not Yet Recruiting → Recruiting 2020-11-17
Trial Details
NCT Number NCT04348045
Lead Sponsor GERCOR - Multidisciplinary Oncology Cooperative Group
Collaborators: AstraZeneca
Conditions Metastatic Pancreatic Adenocarcinoma
Enrollment 307 participants
Start Date 2020-12-07
Primary Completion 2023-06-15 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-25